ACAD ACADIA Pharmaceuticals Inc.
USHealthcareAs of 2026-07-10 14:15
Why ACAD matters now
ACADIA Pharmaceuticals Inc. (ACAD) is a US stock in Healthcare. The latest InvestLog snapshot shows $26.24 with -0.64% on the session and $4.49B in market capitalization; recent performance reads 1-month +5.57% and YTD -19.06%.
The latest financial table shown here is Q1 2026, with revenue of $268.1M, net income of $3.6M, and EPS of $0.02. Investors can compare that operating picture with valuation signals such as P/E 9.48 and FCF yield 5.7%.
The latest indexable market news headline is "RPRX or ACAD: Which Is the Better Value Stock Right Now?" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $33.50; recent insider activity includes BAKER BROS. ADVISORS LP filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
9.48
PEG
0.13
P/B
2.95
P/S
3.38
EV/EBITDA
27.35
DCF Value
$-35.31
FCF Yield
5.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
91.5%
Operating Margin
7.4%
Net Margin
34.3%
ROE
35.6%
ROA
23.4%
ROIC
6.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $268.1M | $3.6M | $0.02 |
| Q4 2025 | $284.0M | $273.6M | $1.60 |
| FY 2025 | $1.07B | $391.0M | $2.29 |
| Q3 2025 | $278.6M | $71.8M | $0.42 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$33.67
Target (Median)
$33.50
Target Range
$29.00 - $40.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.83
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.